Potential therapeutic use of cannabinoid compounds - cannabidiol and delta-9-tetrahydrocannabinol





Cannabidiol; Dronabinol; Tetrahydrocannabinol; Medical marijuana.


Derivatives of Cannabis sativa are being used to treat comorbidities that do not yet have an efficient treatment for damage and symptoms. The cannabinoid compounds - cannabidiol and delta-9-tetrahydrocannabinol have been tested for therapeutic use and several studies seek to elucidate the pharmacological effects of these substances. Thus, the present study gathers information on cannabinoid derivatives and the pharmacological effects already described for the cannabidiol and delta-9-tetrahydrocannabinol compounds. An integrative literature review was performed based on data collected from original articles obtained from the databases: MEDLINE, SciELO, BVS and LILACS, using the terms: cannabinoids, cannabidiol, tetrahydrocannabinol (dronabinol), medical marijuana. Knowledge about endocannabinoid ligands demonstrates that cannabinoid compounds can play a significant role in mediating several neurophysiological processes. Research shows that these derivatives are an important alternative for the treatment of various pathologies, mainly on diseases that still do not have a response or that the response is not as effective. Data reinforce that cannabinoids can be a therapeutic option for patients undergoing chemotherapy assisting in crises resulting from treatment, in addition to assisting in the treatment of spinal trauma, AIDS, multiple sclerosis, peripheral neuropathy, Tourette's syndrome, in the postoperative period - cerebral infarction or other clinical conditions that have a strong association with chronic pain. Although scientific advances demonstrate benefits in the use of cannabinoid compounds, there is still a need for studies to prove the action. Research with Cannabis sativa opens space for the possibility of treating diseases that do not yet have a therapeutic response, making these substances a pharmaceutical hope.


Ahmed, A. I., van den Elsen, G. A., Colbers, A., Kramers, C., Burger, D. M., van der Marck, M. A., & Olde Rikkert, M. G. (2015). Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia. Psychopharmacology, 232(14), 2587–2595. https://doi.org/10.1007/s00213-015-3889-y

Baeeri, M., Rahimifard, M., Daghighi, S. M., Khan, F., Salami, S. A., Moini-Nodeh, S., Haghi-Aminjan, H., Bayrami, Z., Rezaee, F., & Abdollahi, M. (2020). Cannabinoids as anti-ROS in aged pancreatic islet cells. Life sciences, 256, 117969. https://doi.org/10.1016/j.lfs.2020.117969

Barbosa, M. G. A., Barros, E. F. A., Lima, G. R., Silva, G. F., & Souza, P. G. V. D. (2020). O uso do composto de Canabidiol no tratamento da doença de Alzheimer (revisão da literatura). Research, Society and Development, 9(8), e442986073. DOI: 10.33448/rsd-v9i8.6073.

Beaulieu, P., Boulanger, A., Desroches, J., & Clark, A. J. (2016). Medical cannabis: considerations for the anesthesiologist and pain physician. Canadian journal of anaesthesia = Journal canadien d'anesthesie, 63(5), 608–624. https://doi.org/10.1007/s12630-016-0598-x

Brucki, S. M. D., Frota, N. A., Schestatsky, P., Souza, A. H., Carvalho, V. N., Manreza, M. L. G., Mendes, M. F., Comini-Frota, E., Vasconcelos, C., Tumas, V., Ferraz, H. B., Barbosa, E., & Jurno, M. E. (2015). Cannabinoids in neurology – Brazilian Academy of Neurology. Arquivos de Neuro-Psiquiatria, 73(4), 371-374. Epub April 00, 2015.https://doi.org/10.1590/0004-282X20150041

Buhmann, C., Mainka, T., Ebersbach, G., & Gandor, F. (2019). Evidence for the use of cannabinoids in Parkinson's disease. Journal of neural transmission (Vienna, Austria: 1996), 126(7), 913–924. https://doi.org/10.1007/s00702-019-02018-8

De Vries, M., Van Rijckevorsel, D. C., Vissers, K. C., Wilder-Smith, O. H., & Van Goor, H. (2016). Single dose delta-9-tetrahydrocannabinol in chronic pancreatitis patients: analgesic efficacy, pharmacokinetics and tolerability. British journal of clinical pharmacology, 81(3), 525–537. https://doi.org/10.1111/bcp.12811

Devinsky, O., Cross, J. H., & Wright, S. (2017). Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. The New England journal of medicine, 377(7), 699–700. https://doi.org/10.1056/NEJMc1708349

DiFiglia M. (2020). An early start to Huntington's disease. Science (New York, N.Y.), 369(6505), 771–772. https://doi.org/10.1126/science.abd6215

Finseth, T. A., Hedeman, J. L., Brown, R. P., 2nd, Johnson, K. I., Binder, M. S., & Kluger, B. M. (2015). Self-reported efficacy of cannabis and other complementary medicine modalities by Parkinson's disease patients in colorado. Evidence-based complementary and alternative medicine: eCAM, 2015, 874849. https://doi.org/10.1155/2015/874849

Garcia, T. R., Cruz, M. C. A., Silva, G. O. A., Cardoso, E. F., & Arruda, J. T. (2020). Canabidiol para o tratamento de pacientes com Síndrome de West e epilepsia. Research, Society and Development, 9(9), e420997267. DOI: 10.33448/rsd-v9i9.7267.

Gaston, T. E., & Friedman, D. (2017). Pharmacology of cannabinoids in the treatment of epilepsy. Epilepsy & behavior: E&B, 70(Pt B), 313–318. https://doi.org/10.1016/j.yebeh.2016.11.016

Grosso, Adriana F. (2020). Cannabis: de planta condenada pelo preconceito a uma das grandes opções terapêuticas do século. Journal of Human Growth and Development, 30(1), 94-97. https://dx.doi.org/10.7322/jhgd.v30.9977

Hasenoehrl, C., Taschler, U., Storr, M., & Schicho, R. (2016). The gastrointestinal tract - a central organ of cannabinoid signaling in health and disease. Neurogastroenterology and motility: the official journal of the European Gastrointestinal Motility Society, 28(12), 1765–1780. https://doi.org/10.1111/nmo.12931

Hoffenberg, E. J., Newman, H., Collins, C., Tarbell, S., & Leinwand, K. (2017). Cannabis and Pediatric Inflammatory Bowel Disease: Change Blossoms a Mile High. Journal of pediatric gastroenterology and nutrition, 64(2), 265–271. https://doi.org/10.1097/MPG.0000000000001393

Huntsman, R. J., Tang-Wai, R., Alcorn, J., Vuong, S., Acton, B., Corley, S., Laprairie, R., Lyon, A. W., Meier, S., Mousseau, D. D., Newmeyer, D., Prosser-Loose, E., Seifert, B., Tellez-Zenteno, J., Huh, L., Leung, E., & Major, P. (2019). Dosage Related Efficacy and Tolerability of Cannabidiol in Children With Treatment-Resistant Epileptic Encephalopathy: Preliminary Results of the CARE-E Study. Frontiers in neurology, 10, 716. https://doi.org/10.3389/fneur.2019.00716

Ibeas Bih, C., Chen, T., Nunn, A. V., Bazelot, M., Dallas, M., & Whalley, B. J. (2015). Molecular Targets of Cannabidiol in Neurological Disorders. Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics, 12(4), 699–730. https://doi.org/10.1007/s13311-015-0377-3

Ilyasov, A. A., Milligan, C. E., Pharr, E. P., & Howlett, A. C. (2018). The Endocannabinoid System and Oligodendrocytes in Health and Disease. Frontiers in neuroscience, 12, 733. https://doi.org/10.3389/fnins.2018.00733

Kleckner, A. S., Kleckner, I. R., Kamen, C. S., Tejani, M. A., Janelsins, M. C., Morrow, G. R., & Peppone, L. J. (2019). Opportunities for cannabis in supportive care in cancer. Therapeutic advances in medical oncology, 11, 1758835919866362. https://doi.org/10.1177/1758835919866362

Klotz, K. A., Schulze-Bonhage, A., Antonio-Arce, V. S., & Jacobs, J. (2018). Cannabidiol for Treatment of Childhood Epilepsy-A Cross-Sectional Survey. Frontiers in neurology, 9, 731. https://doi.org/10.3389/fneur.2018.00731

Koppel B. S. (2015). Cannabis in the Treatment of Dystonia, Dyskinesias, and Tics. Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics, 12(4), 788–792. https://doi.org/10.1007/s13311-015-0376-4

Korem, N., Zer-Aviv, T., Ganon-Elazar, E., Abush, H. & Akirav, I. (2016). Targeting the endocannabinoid system to treat anxiety-related disorders. Journal of Basic and Clinical Physiology and Pharmacology, 27(3), 193-202. https://doi.org/10.1515/jbcpp-2015-0058

Medeiros, D. N., Ribeiro, J. F. S., & Trajano, L. A. S. N. (2021). Psicose induzida por drogas recreativas: uma revisão de literatura. Research, Society and Development, 10(2), e21910212459. DOI: 10.33448/rsd-v10i2.12459.

Medeiros, F. C., Soares, P. B., Jesus, R. A., Teixeira, D. G., Alexandre, M. M., & Sabec, G. Z. (2020). Medicinal use of Cannabis sativa (Cannabaceae) as an alternative in the treatment of epilepsy. Brazilian Journal of Development, 6(6), 41510-41523. DOI: https://doi.org/10.34117/bjdv6n6-623

Murkar, A., Kent, P., Cayer, C., James, J., Durst, T., & Merali, Z. (2019). Cannabidiol and the Remainder of the Plant Extract Modulate the Effects of Δ9-Tetrahydrocannabinol on Fear Memory Reconsolidation. Frontiers in behavioral neuroscience, 13, 174. https://doi.org/10.3389/fnbeh.2019.00174

Rodrigues, A. P. L. S., Lopes, I. S., & Mourão, V. L. A. (2021). “Ninguém está falando em liberação da droga”: ressignificação da maconha nos programas matinais das redes Globo e Record. Research, Society and Development, 10(2), e16910212344. DOI: 10.33448/rsd-v10i2.12344.

Rosenberg, E. C., Patra, P. H., & Whalley, B. J. (2017). Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection. Epilepsy & behavior: E&B, 70(Pt B), 319–327. https://doi.org/10.1016/j.yebeh.2016.11.006

Silva, G. R. M., Reis, G. K., Lopes, K. A., Rebelo, L. S., Alencar, S. R. F., Serra, V. S., & Lopes, G. S. (2020). Enfermagem: um estudo da fisiopatologia do Alzheimer e os seus tratamentos alternativos com células-tronco e cannabis. Research, Society and Development, 9(11), e39891110094. DOI: 10.33448/rsd-v9i11.10094.

Simmerman, E., Qin, X., Yu, J. C., & Baban, B. (2019). Cannabinoids as a Potential New and Novel Treatment for Melanoma: A Pilot Study in a Murine Model. The Journal of surgical research, 235, 210–215. https://doi.org/10.1016/j.jss.2018.08.055

Solowij, N., Broyd, S. J., Beale, C., Prick, J. A., Greenwood, L. M., van Hell, H., Suo, C., Galettis, P., Pai, N., Fu, S., Croft, R. J., Martin, J. H., & Yücel, M. (2018). Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users: A Pragmatic Open-Label Clinical Trial. Cannabis and cannabinoid research, 3(1), 21–34. https://doi.org/10.1089/can.2017.0043

Stampanoni Bassi, M., Sancesario, A., Morace, R., Centonze, D., & Iezzi, E. (2017). Cannabinoids in Parkinson's Disease. Cannabis and cannabinoid research, 2(1), 21–29. https://doi.org/10.1089/can.2017.0002

Van der Flier, F. E., Kwee, C. M. B., Cath, D. C. et al. (2019). Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias: study protocol of a randomized controlled trial. BMC Psychiatry 19, 69. https://doi.org/10.1186/s12888-019-2022-x

Van Rensburg, R., Pillay-Fuentes Lorente, V., Blockman, M., Moodley, K., Wilmshurst, J. M., & Decloedt, E. H. (2020). Medical cannabis: What practitioners need to know. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 110(3), 192–196. https://doi.org/10.7196/SAMJ.2020.v110i3.14403

Villas Bôas, G. K., & Rezende, M. A. (2020). Discussão sobre o acesso aos medicamentos derivados da Cannabis à luz da Inovação em Saúde no Brasil. Rev Fitos. Rio de Janeiro. 14(2), 259-284. http://dx.doi.org/10.32712/2446-4775.2020.960



How to Cite

RIBEIRO, G. R.; NERY, L. G.; COSTA, A. C. M. M.; OLIVEIRA, G. S.; VAZ, R. L.; FONTOURA, H. de S.; ARRUDA, J. T. Potential therapeutic use of cannabinoid compounds - cannabidiol and delta-9-tetrahydrocannabinol. Research, Society and Development, [S. l.], v. 10, n. 4, p. e25310413844, 2021. DOI: 10.33448/rsd-v10i4.13844. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/13844. Acesso em: 7 may. 2021.



Health Sciences